Altre lingue Affimed N.V.

Azioni

AFMD

NL0015001ZQ0

Tempo reale stimato Cboe BZX Altri mercati azionari 17:23:50 09/07/2024			Variaz. 5gg	Var. 1 gen.
4,945 ^USD	+1,33%		-5,33%	-21,92%

12/06	Transcript : Affimed N.V., Q1 2024 Earnings Call, Jun 12, 2024
12/06	Affimed N.V. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Affimed N : .V Form 6 K	26/06
AFFIMED REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND BUSINESS UPDATE	13/06
Affimed N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	12/06
Affimed Reports First Quarter 2024 Financial Results & Business Update	12/06
AFFIMED TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS AND CORPORATE UPDATE ON JUNE 12, 2024	06/06
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024	05/06
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort	01/06
Affimed N.V. Provides Follow-Up Data of AFM24 Plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-Type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort	01/06
Affimed Says US FDA Grants Fast-Track Designation for Potential Lung Cancer Therapy	29/05
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer	29/05
Affimed N.V. Receives Fast Track Designation for Combination Therapy of Afm24 with Atezolizumab for Egfr Wild-Type Non-Small Cell Lung Cancer	29/05
Affimed Announces Annual General Meeting of Shareholders	28/05
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024	23/05
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024	23/05
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress	14/05
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology	24/04
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Affimed Reports 2023 Financial Results and Operational Progress	28/03
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	21/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Affimed N.V.

Azioni

AFMD

NL0015001ZQ0

Altre lingue

Filtri